相关实验视频

Updated: Jul 19, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

前期使用plerixa的结果,用于在生殖细胞瘤患者的动员

Jaimie Cohen¹, Shreya Shah¹, Katrina Piedra¹

¹Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA.

Hematology, transfusion and cell therapy

|March 14, 2024

概括

前期用于生殖细胞瘤患者的plerixa显著改善了干细胞采集成功率,其中94%的采集成功. 这种方法促进了更有效的干细胞动员,用于自身造血干细胞移植.

科学领域:

血液学血液学血液学
在瘤学瘤学.
干细胞移植干细胞移植

背景情况:

高剂量化疗与自身造血干细胞移植 (auto-HSCT) 提供了复发/耐药生殖细胞瘤 (GCTs) 的改善生存率.
显著比例的GCT患者是不良的动员者,在多次先前治疗后复杂化治疗.
关于前期plerixafor在GCT患者的疗效的数据有限.

研究的目的:

在GCT患者中评估使用前期plerixafor进行外周血液CD34+细胞采集的成功率.
评估前期plerixafor对干细胞调动效率的影响.
描述前期接受plerixafor的GCT患者的自动HSCT结果.

主要方法:

对接受前期plerixafor调动的成年GCT患者的回顾性,单中心图表审查.
2013年1月1日至2021年8月31日期间收集的数据.
主要终点:成功采集CD34+细胞 (4天内≥4×10^6细胞/千克).

主要成果:

在16名 (94%) 患者中,有15名患者在中位数为1天的时间内成功采集干细胞.
所有患者都进行了自动HSCT,75%完成了计划的移植.
12个月的生存率为50%.

结论:

前期的plerixafor使用在改善GCT患者的干细胞调动方面具有临床有效性.
这一策略增加了CD34+细胞的产量,并减少了亚菲雷西斯天数,潜在地改善了治疗治疗的时间.
更大的随机试验是有必要的,以证实这些发现在这个患者群体.

关键词:

自主造血干细胞移植自主造血干细胞移植细菌细胞瘤的发生在Plerixafor上使用.干细胞动员干细胞的动员

更多相关视频

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos

Rapid in vivo Drug Response Prediction Using Leukemia Cell Grafts in Zebrafish Embryos

Published on: May 23, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...